The amygdala–ventral pallidum pathway contributes to a hypodopaminergic state in the ventral tegmental area during protracted abstinence from chronic cocaine
British Journal of Pharmacology · 2023
DOI: 10.1111/bph.16034 ↗At a glance
Journal article in British Journal of Pharmacology, 2023. Written by Adélie Salin and 4 co-authors. Institution: Université de Poitiers, INSERM, U-1084, Laboratoire des Neurosciences Expérimentales et Cliniques, Poitiers, France. Major MEDLINE topics: Cocaine, Basal Forebrain. Cited 7 times so far (Crossref); 63 references. The full text is freely available (open access, CC BY 4.0). Funded by: Institut National de la Santé et de la Recherche Médicale, Centre National pour la Recherche Scientifique et Technique, Université de Poitiers.
Abstract (original language)
Background and Purpose Incubation of craving, the progressive increase in drug seeking over the first weeks of abstinence, is associated with temporal changes during abstinence in the activity of several structures involved in drug‐seeking behaviour. Decreases of dopamine (DA) release and DA neuronal activity (hypodopaminergic state) have been reported in the ventral tegmental area (VTA) during cocaine abstinence, but the mechanisms underlying these neuroadaptations are not well understood. We investigated the potential involvement of a VTA inhibiting circuit (basolateral amygdala [BLA]–ventral pallidum [VP] pathway) in the hypodopaminergic state associated with abstinence from chronic cocaine. Experimental Approach In a model of cocaine self‐administration, we performed in vivo electrophysiological recordings of DA VTA neurons and BLA neurons from anaesthetised rats during early and protracted abstinence and evaluated the involvement of the BLA–VP pathway using a pharmacological approach. Key Results We found significant decreases in VTA DA population activity and significant increases in BLA activity after protracted but not after short‐term abstinence from chronic cocaine. The decrease in VTA DA activity was restored by pharmacological inhibition of the activity of either the BLA or the VP, suggesting that these regions exert a negative influence on DA activity. Conclusion and Implications Our study sheds new lights on neuroadaptations occurring during incubation of craving leading to relapse. In particular, we describe the involvement of the BLA–VP pathway in cocaine‐induced decreases of DA activity in the VTA. This study adds important information about the specific brain network dysfunctions underlying hypodopaminergic activity during abstinence.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Université de Poitiers, INSERM, U-1084, Laboratoire des Neurosciences Expérimentales et Cliniques, Poitiers, France.
- Université de Rennes, Institut Numecan INRAE, INSERM, Rennes, France.
- CHU de Poitiers, Poitiers, France.
ORCID profiles: Pauline Belujon
Funding
- Institut National de la Santé et de la Recherche Médicale
- Centre National pour la Recherche Scientifique et Technique
- Université de Poitiers
- Agence Nationale de la Recherche
Cite
APA
Salin, A., Dugast, E., Lardeux, V., Solinas, M., & Belujon, P. (2023). The amygdala–ventral pallidum pathway contributes to a hypodopaminergic state in the ventral tegmental area during protracted abstinence from chronic cocaine. British Journal of Pharmacology. https://doi.org/10.1111/bph.16034
Vancouver
Salin A, Dugast E, Lardeux V, Solinas M, Belujon P. The amygdala–ventral pallidum pathway contributes to a hypodopaminergic state in the ventral tegmental area during protracted abstinence from chronic cocaine. British Journal of Pharmacology. 2023. doi:10.1111/bph.16034
BibTeX
@article{Salin2023,
author = {Salin, Adélie and Dugast, Emilie and Lardeux, Virginie and Solinas, Marcello and Belujon, Pauline},
title = {The amygdala–ventral pallidum pathway contributes to a hypodopaminergic state in the ventral tegmental area during protracted abstinence from chronic cocaine},
journal = {British Journal of Pharmacology},
year = {2023},
doi = {10.1111/bph.16034}
}
EUVIMED